Cargando…
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint inhibitors (ICIs). Both treatment options have imp...
Autores principales: | Rassy, Elie, Flippot, Ronan, Albiges, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081462/ https://www.ncbi.nlm.nih.gov/pubmed/32215057 http://dx.doi.org/10.1177/1758835920907504 |
Ejemplares similares
-
PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020) -
Tivozanib in renal cell carcinoma: a new approach to previously
treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020) -
Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
por: Davis, Ian D.
Publicado: (2022) -
Cytoreductive nephrectomy in the current treatment
algorithm
por: Kuusk, Teele, et al.
Publicado: (2019) -
Guiding management of therapy in prostate cancer: time to switch from
conventional imaging to PSMA PET?
por: Alipour, Ramin, et al.
Publicado: (2019)